LBA4 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase III KEYNOTE-522 study

P. Schmid, J. Cortés, R. Dent, HL McArthur, L. Pusztai, Sherko Kümmel, C. Denkert, Y.H. Park, R. Hui, N. Harbeck, M. Takahashi, S-A. Im, M. Untch, P.A. Fasching, F. Cardoso, Jing Zhao, Xiaoyan Zhou, Konstantinos Tryfonidis, Gursel Aktan, J. O'Shaughnessy